Pharmaceuticals, Biotechnology & Life Sciences

Explore aTyr Pharma’s volatile biotech journey, protein therapeutics focus, and financial insights for investors and industry watchers.

BB Biotech AG reports a CHF 578 million net profit in 2025, a sharp rise driven by a successful Q4 and active portfolio management of U.S. and European drug‑development firms.

Heidelberg Pharma AG, a German biopharma leader, focuses on innovative cancer therapies and recent milestone payments from Takeda, driving future growth in oncology.

Hyperliquid launches a Washington, D.C. policy center to shape U.S. DeFi and perpetual derivative rules, positioning itself as a crypto‑policy influencer.

Rubicon Organics opens its Cascadia facility, boosting specialty cannabis and organic pharma production while showing a low‑PE, undervalued stock poised for growth.

Capricor Therapeutics, a clinical‑stage biotech focused on Duchenne muscular dystrophy, drew a high‑profile stake from Tang Capital, boosting investor confidence and highlighting its promising yet volatile stock prospects.

QIAGEN NV boosts its single‑cell genomics lineup with Parse Biosciences Evercode V4, expands into Japan’s point‑of‑care market, and navigates industry consolidation while maintaining stable equity performance.

Discover how Traws Pharma’s Phase‑2 COVID‑19 study milestone fuels its promising cancer‑drug pipeline, market insights, and investor outlook.

Stevanato Group SpA’s glass packaging expertise fuels its $4.36B market cap and strong NYSE performance, driving growth for global pharma supply chains.

Northwest Biotherapeutics